Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell lines Retraction in /10.3892/mmr.2021.12080

Wang,Li; Wu,Jianzhong; Lu,Jianwei; Ma,Rong; Sun,Dawei; Tang,Jinhai

doi:10.3892/mmr.2014.2819

Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell lines

Retraction in: /10.3892/mmr.2021.12080

Authors:
- Li Wang
- Jianzhong Wu
- Jianwei Lu
- Rong Ma
- Dawei Sun
- Jinhai Tang
View Affiliations

Affiliations: First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210046, P.R. China, Department of General Surgery, The Affiliated Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing, Jiangsu 210000, P.R. China
Published online on: October 30, 2014 https://doi.org/10.3892/mmr.2014.2819
Pages: 931-939
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is the second leading cause of cancer‑related mortality in females worldwide. Therefore, identifying alternative strategies to combat the disease mortality is important. The aim of the present study was to investigate the effect of tanshinone I (Tan I) on the tumorigenicity of estrogen‑responsive MCF‑7 and estrogen‑independent MDA‑MB‑453 human breast cancer cells. The cytotoxicity of Tan I was evaluated using a Cell Counting Kit‑8 assay, the apoptosis and cell cycle distribution were detected using flow cytometry and the cell morphology was observed using a fluorescence microscope. In addition, the cell cycle regulatory proteins and apoptosis‑associated proteins involved in the phosphatidylinositide 3‑kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway were detected using western blot analysis using specific protein antibodies. The MCF‑7 and MDA‑MB‑453 cells were equally sensitive to Tan I regardless of their responsiveness to estrogen. Tan I exerted similar antiproliferative activities and induction of apoptosis, resulting in S phase arrest accompanied by decreases in cyclin B and increases in cyclin E and cyclin A proteins, which may have been associated with the upregulation of cyclin‑dependent kinase inhibitors p21Cip1 and p27Kip1. In addition, Tan I was found to downregulate anti‑apoptotic and upregulate associated apoptotic components of the PI3K/Akt/mTOR signaling pathway. Notably, treatment with the PI3K inhibitor, LY294002, decreased the levels of phosphorylated (p)‑PI3K, p‑Akt and p‑mTOR. These results clearly indicated that the mechanism of action of Tan I involved, at least partially, an effect on the PI3K/Akt/mTOR signaling pathway, providing new information for anticancer drug design and development.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
2	Lee WYW, Chiu LCM and Yeung JHK: Cytotoxicity of major tanshinones isolated from Danshen (Salvia miltiorrhiza) on HepG2 cells in relation to glutathione perturbation. Food Chem Toxicol. 46:328–338. 2008. View Article : Google Scholar
3	Liu JJ, Zhang Y, Lin DJ and Xiao RZ: Tanshinone IIA inhibits leukemia THP-1cell growth by induction of apoptosis. Oncol Rep. 21:1075–1081. 2009.PubMed/NCBI
4	Su CC and Lin YH: Tanshinone IIA inhibits human breast cancer cells through increased Bax to Bcl-xL ratios. Int J Mol Med. 22:357–361. 2008.PubMed/NCBI
5	Lee CY, Sher HF, Chen HW, et al: Anticancer effects of tanshinone I in human non-small cell lung cancer. Mol Cancer Ther. 7:3527–3538. 2008. View Article : Google Scholar : PubMed/NCBI
6	Nizamutdinova IT, Lee GW, Son KH, et al: Tanshinone I effectively induces apoptosis in estrogen receptor-positive (MCF-7) and estrogen receptor-negative (MDA-MB-231) breast cancer cells. Int J Oncol. 33:485–491. 2008.PubMed/NCBI
7	Zhou LM, Zuo Z and Chow MSS: Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol. 45:1345–1359. 2005. View Article : Google Scholar : PubMed/NCBI
8	Li YL, Gong Y, Li LL, Abdolmaleky HM and Zhou JR: Bioactive tanshinone I inhibits the growth of lung cancer in part via downregulation of Aurora A function. Mol Carcinog. 52:535–543. 2012. View Article : Google Scholar : PubMed/NCBI
9	Paulovich AG and Hartwell LH: A checkpoint regulates the rate of progression through S phase in Saccharomyces cerevisiae in response to DNA damage. Cell. 82:841–847. 1995. View Article : Google Scholar : PubMed/NCBI
10	Walker JL and Assoian RK: Integrin-dependent signal transduction regulating cyclin D1 expression and G1 phase cell cycle progression. Cancer Metastasis Rev. 24:383–393. 2005. View Article : Google Scholar : PubMed/NCBI
11	Lew DJ and Kornbluth S: Regulatory roles of cyclin dependent kinase phosphorylation in cell cycle control. Curr Opin Cell Biol. 8:795–804. 1996. View Article : Google Scholar : PubMed/NCBI
12	Kawauchi K, Ogasawara T, Yasuyama M, Otsuka K and Yamada O: The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem. 9:550–559. 2009. View Article : Google Scholar : PubMed/NCBI
13	Downward J: Signal transduction-lipid-regulated kinases: Some common themes at last. Science. 279:673–674. 1998. View Article : Google Scholar : PubMed/NCBI
14	Foster KG and Fingar DC: Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem. 285:14071–14077. 2010. View Article : Google Scholar : PubMed/NCBI
15	Benjamin D, Colombi M, Moroni C and Hall MN: Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov. 10:868–880. 2011. View Article : Google Scholar : PubMed/NCBI
16	Justin C and Ben Ho P: Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy. J Mammary Gland Biol Neoplasia. 17:205–216. 2012. View Article : Google Scholar
17	Zhang YJ, Dai Q, Sun DF, et al: mTOR signaling pathway is a target for the treatment of colorectal cancer. Ann Surg Oncol. 6:2617–2628. 2009. View Article : Google Scholar
18	Maira SM, Voliva C and Garcia-Echeverria C: Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery. Expert Opin Ther Targets. 12:223–238. 2008. View Article : Google Scholar : PubMed/NCBI
19	Li XJ, Ji MH, Zhong SL, et al: MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting notch1. Arch Med Res. 43:514–521. 2012. View Article : Google Scholar : PubMed/NCBI
20	Strong AL, Strong TA, Rhodes LV, et al: Obesity associated alterations in the biology of adipose stem cells mediate enhanced tumorigenesis by estrogen dependent pathways. Breast Cancer Res. 15:R1022013. View Article : Google Scholar : PubMed/NCBI
21	Mousavi M, Montazeri A, Mohagheghi MA, et al: Breast Cancer in Iran: An Epidemiological Review. Breast J. 13:383–391. 2007. View Article : Google Scholar : PubMed/NCBI
22	Mosaddik MA: In vitro cytotoxicity of tanshinones isolated from Salvia miltiorrhiza Bunge against P388 lymphocytic leukemia cells. Phytomedicine. 10:682–685. 2003. View Article : Google Scholar : PubMed/NCBI
23	Nizamutdinova IT, Lee GW, Lee JS, et al: Tanshinone I suppresses growth and invasion of human breast cancer cells, MDA-MB-231, through regulation of adhesion molecules. Carcinogenesis. 29:1885–1892. 2008. View Article : Google Scholar : PubMed/NCBI
24	Trivedi PP, Roberts PC, Wolf NA and Swanborg RH: NK cells inhibit T cell proliferation via p21-mediated cell cycle arrest. J Immunol. 174:4590–4597. 2005. View Article : Google Scholar : PubMed/NCBI
25	Gong Y, Li Y, Abdolmaleky HM, Li L and Zhou JR: Tanshinones inhibit the growth of breast cancer cells through epigenetic modification of aurora A expression and function. PLoS One. 7:e336562012. View Article : Google Scholar : PubMed/NCBI
26	Gong Y, Li Y, Lu Y, et al: Bioactive tanshinones in Salvia miltiorrhiza inhibit the growth of prostate cancer cells in vitro and in mice. Int J Cancer. 129:1042–1052. 2011. View Article : Google Scholar :
27	Hseu YC, Chen SC, Chen HC, Liao JW and Yang HL: Antrodia camphorata inhibits proliferation of human breast cancer cells in vitro and in vivo. Food Chem Toxicol. 46:2680–2688. 2008. View Article : Google Scholar : PubMed/NCBI
28	Denicourt C and Dowdy SF: Cip/Kip proteins: more than just CDKs inhibitors. Genes Dev. 18:851–855. 2004. View Article : Google Scholar : PubMed/NCBI
29	Gartel AL and Tyner AL: The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther. 1:639–649. 2002.PubMed/NCBI
30	Cheng YL, Lee SC, Lin SZ, et al: Anti-proliferative A549 human activity of Bupleurum scrozonerifolium in lung cancer cells in vitro and in vivo. Cancer Lett. 222:183–193. 2005. View Article : Google Scholar : PubMed/NCBI
31	Tokunaga E, Oki E, Egashira A, et al: Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets. 8:27–36. 2008. View Article : Google Scholar : PubMed/NCBI
32	Manning BD and Cantley LC: AKT/PKB signaling: navigating downstream. Cell. 129:1261–1274. 2007. View Article : Google Scholar : PubMed/NCBI
33	Janku F, Mc Conkey DJ, Hong DS and Kurzrock R: Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol. 8:528–539. 2011. View Article : Google Scholar : PubMed/NCBI
34	Deng R, Tang J, Ma JG, et al: PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation. Oncogene. 30:944–955. 2011. View Article : Google Scholar
35	Umemura S, Yoshida S, Ohta Y, Naito K, Osamura RY and Tokuda Y: Increased phosphorylation of Akt in triple-negative breast cancers. Cancer Sci. 98:1889–1892. 2007. View Article : Google Scholar : PubMed/NCBI
36	Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI
37	Krystal GW, Sulanke G and Litz J: Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther. 1:913–922. 2002.PubMed/NCBI
38	Liu JJ, Liu WD, Yang HZ, et al: Inactivation of PI3k/Akt signal ing pathway and activation of caspase-3 are involved in tanshinone I-induced apoptosis in myeloid leukemia cells in vitro. Ann Hematol. 89:1089–1097. 2010. View Article : Google Scholar : PubMed/NCBI
39	Cai N, Dai SD, Liu NN, Liu LM, Zhao N and Chen L: PI3K/AKT/mTOR signaling pathway inhibitors in proliferation of retinal pigment epithelial cells. Int J Ophthalmol. 5:675–680. 2012.
40	Yang HL, Chen CS, Chang WH, et al: Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by antrodiacamphorata. Cancer Lett. 231:215–227. 2006. View Article : Google Scholar : PubMed/NCBI
41	Mandal D, Moitra PK, Saha S and Basu J: Caspase 3 regulates phosphatidylserine externalization and phagocytosis of oxidatively stressed erythrocytes. FEBS Lett. 513:184–188. 2002. View Article : Google Scholar : PubMed/NCBI
42	Jankiewicz M, Groner B and Desrivieres S: Mammalian target of rapamycin regulates the growth of mammary epithelial cells through the inhibitor of deoxyribonucleic acid binding Id1 and their functional differentiation through Id2. Mol Endocrinol. 20:2369–2381. 2006. View Article : Google Scholar : PubMed/NCBI
43	Carraway H and Hidalgo M: New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res. 6:219–224. 2004. View Article : Google Scholar : PubMed/NCBI
44	Vu C and Fruman DA: Target of rapamycin signaling in leukemia and lymphoma. Clin Cancer Res. 16:5374–5380. 2010. View Article : Google Scholar : PubMed/NCBI
45	Dazert E and Hall MN: mTOR signaling in disease. Curr Opin Cell Biol. 23:744–755. 2011. View Article : Google Scholar : PubMed/NCBI
46	Johnsen JI, Segerstrom L, Orrego A, et al: Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene. 27:2910–2922. 2008. View Article : Google Scholar
47	Chesler L, Schlieve C, Goldenberg DD, et al: Inhibition of phosphatidylinositol 3-kinase destabilizes MYCN protein and blocks malignant progression in neuroblastoma. Cancer Res. 66:8139–8146. 2006. View Article : Google Scholar : PubMed/NCBI